主动撤回重新递交,乐普生物EGFR ADC新药上市申请获受理

医麦客
07 Mar

2025年3月7日医麦客新闻 eMedClub News2025年3月6日,据CDE显示,乐普生物重新提交的全球首创EGFR ADC新药MRG003的上市申请已经获得受理,受理号为CXSS2500034。乐普生物曾发布公告表示,日前收到药品通知批件,是因为公司为补充提交相关资料而主动撤回申请所导致,并非临床试验的数据问题,不影响上市。MRG003由EGFR靶向单克隆抗体与强效的微管抑制有效载荷甲基...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10